Replies to post #12260 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: HR and HIT

Thanks, Urche—you’re quite right and my post was out to lunch: Refludan, Argatroban, and HIT/HITTS are irrelevant to what GTC is attempting to do in CABG/HR, which is an altogether separate indication from HIT/HITTS.

Thus, the short answer to goseek’s question in #msg-30313699 (“Will ATryn be able to compete on price vs the alternative(s) used for HR?”) is that there isn’t any bona fide alternative to ATryn in the CABG/HR setting inasmuch as Thrombate (the only currently approved antithrombin in the US) is available in very limited quantities. Regards, Dew


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”